NKGen Biotech Korea Q1 2026: Revenue Up, Net Loss Widens, Delisting Risk Remains

Q1 2026 consolidated revenue KRW 1.57B (up 10.6% YoY from KRW 1.42B), operating loss narrowed to KRW 1.21B (from KRW 1.82B)
Net loss widened to KRW 1.27B (from KRW 0.68B) mainly due to FX losses and other financial costs
First quarter under new majority shareholder NKGen Biotech (64.14% stake); KRW 168M revenue from parent
Cash and cash equivalents fell 70% to KRW 0.29B (including short-term financial instruments: KRW 1.92B)
Trade receivables KRW 5.1B with 78.4% allowance (KRW 4.0B); full allowance on loans to subsidiaries
Equity KRW 6.17B (down from KRW 7.10B at year-end 2025), accumulated deficit KRW 348.8B
SNK01 (troculeucel) granted FDA Fast Track designation (Feb 2025); Alzheimer's Ph1/2a ongoing in US/Canada
SNK02 (allogeneic NK): Ph1 solid tumor in US, Ph1/2a gastric cancer IND approved in Korea
NK Vue® Kit long-term supply contracts: order backlog KRW 1.5 trillion (through 2032), recognized revenue KRW 2.85B
Stock delisting decision appealed; injunction filed with court; trading suspension continues